3626 results for «394»
3626 results
Tailored transfemoral TAVI in complex anatomies - LIVE Case
11 Sep 2025 – From PCR Rio Valves 2025
Supported by an unrestricted educational grant from Medtronic
An 89-year-old male with hypertension, dyslipidemia, current smoking, stage III kidney disease, and a history of diagonal PCI in 2010 presented with severe symptomatic aortic stenosis and a small annulus (410 mm²), with RBBB on ECG.
Via bilateral femoral access,...
The role of mitral TEER in advanced heart failure
11 Sep 2025 – From PCR Rio Valves 2025
This session delves into the role of mitral transcatheter edge-to-edge repair (TEER) in advanced heart failure patients. Understand the indications for mitral TEER in severe left ventricular dysfunction, prognostic challenges in heart failure with severe mitral regurgitation, and review therapeutic alternatives including the pathway from TEER...
Redo TAVI
12 Sep 2025 – From PCR Rio Valves 2025
This session focuses on the challenges and strategies of redo TAVI, from careful planning to valve selection and tailored procedural approaches. Learn how to manage different valve platforms, optimise outcomes in valve-in-valve scenarios, and prevent complications such as coronary obstruction through real case discussions.
Controlled ring expansion during aortic valve-in-valve: a proof-of-concept CT-scan analysis
24 Jun 2024
Analyze this EIJ image to see how surgical aortic bioprostheses with expandable ring technology can significantly enhance future ViV procedures.
Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial
20 Sep 2022
Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.
It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...
Author
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!
17 Oct 2020
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.
Author
